ESTRO 2021 Abstract Book

S1138

ESTRO 2021

Conclusion The increase in tumour ADC suggests diffusion MRI can be used as an early quantitative biomarker of treatment response. These results warrant further evaluation with long-term follow-up to determine whether it can predict for progression free survival in this group of patients at risk of disease relapse. Evaluation of ADC response may predict clinical outcomes and allow stratification of patients who may benefit from treatment intensification such as focal dose escalation to the tumour or dose escalation using brachytherapy boost. PO-1388 1.5 T MR-guided SBRT for oligorecurrent prostate cancer: preliminary report of feasibility and PROMs F. Cuccia 1 , R. Mazzola 1 , V. Figlia 2 , M. Rigo 2 , L. Nicosia 2 , N. Giaj-Levra 2 , F. Ricchetti 2 , C. Vitale 2 , G. Attinà 2 , E. Pastorello 2 , G. Di Paola 3 , A. De Simone 2 , D. Gurrera 2 , S. Naccarato 4 , G. Sicignano 4 , R. Ruggieri 2 , F. Alongi 2,5 1 Sacro Cuore Don Calabria Hospital , Advanced Radiation Oncology Department, Negrar di Valpolicella, Italy; 2 Sacro Cuore Don Calabria Hospital, Advanced Radiation Oncology Department, Negrar di Valpolicella, Italy; 3 University of Palermo, Independent Statistics Consultant, Palermo, Italy; 4 Sacro Cuore Don Calabria Hospital, Advanced Radiation Oncology Department, Negrar di Valpolicella, Italy; 5 University of Brescia, Radiation Oncology , Brescia, Italy

Purpose or Objective To report preliminary data on feasibility and patient-reported outcomes following PSMA-PET/CT guided SBRT